DE69433348D1 - Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Hemmung der LDL Oxidation und der Atherosclerose - Google Patents

Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Hemmung der LDL Oxidation und der Atherosclerose

Info

Publication number
DE69433348D1
DE69433348D1 DE69433348T DE69433348T DE69433348D1 DE 69433348 D1 DE69433348 D1 DE 69433348D1 DE 69433348 T DE69433348 T DE 69433348T DE 69433348 T DE69433348 T DE 69433348T DE 69433348 D1 DE69433348 D1 DE 69433348D1
Authority
DE
Germany
Prior art keywords
medicament
raloxifene
atherosclerosis
analogs
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69433348T
Other languages
English (en)
Other versions
DE69433348T2 (de
Inventor
Steven Harold Zuckerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69433348D1 publication Critical patent/DE69433348D1/de
Publication of DE69433348T2 publication Critical patent/DE69433348T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Semiconductor Lasers (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Finger-Pressure Massage (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69433348T 1993-12-21 1994-12-19 Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Hemmung der LDL Oxidation und der Atherosclerose Expired - Fee Related DE69433348T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17060693A 1993-12-21 1993-12-21
US170606 1993-12-21

Publications (2)

Publication Number Publication Date
DE69433348D1 true DE69433348D1 (de) 2003-12-24
DE69433348T2 DE69433348T2 (de) 2004-08-26

Family

ID=22620568

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69433348T Expired - Fee Related DE69433348T2 (de) 1993-12-21 1994-12-19 Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Hemmung der LDL Oxidation und der Atherosclerose
DE69433578T Expired - Fee Related DE69433578T2 (de) 1993-12-21 1994-12-19 Hemmung der Endprodukte fortgeschrittener Glykolisierung
DE69428882T Expired - Fee Related DE69428882T2 (de) 1993-12-21 1994-12-19 Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Behandlung von Atherosklerose und ischämischer Herzerkrankungen

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE69433578T Expired - Fee Related DE69433578T2 (de) 1993-12-21 1994-12-19 Hemmung der Endprodukte fortgeschrittener Glykolisierung
DE69428882T Expired - Fee Related DE69428882T2 (de) 1993-12-21 1994-12-19 Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Behandlung von Atherosklerose und ischämischer Herzerkrankungen

Country Status (20)

Country Link
EP (3) EP0963756B1 (de)
JP (1) JPH07196498A (de)
KR (1) KR950016722A (de)
CN (1) CN1095663C (de)
AT (3) ATE207749T1 (de)
AU (1) AU698389B2 (de)
CA (1) CA2138508A1 (de)
CZ (1) CZ286365B6 (de)
DE (3) DE69433348T2 (de)
DK (2) DK1095654T3 (de)
ES (3) ES2163425T3 (de)
HU (1) HUT71476A (de)
IL (1) IL112034A (de)
NO (1) NO313083B1 (de)
NZ (1) NZ270162A (de)
PT (3) PT664121E (de)
RU (1) RU2127592C1 (de)
TW (1) TW427902B (de)
UA (1) UA39941C2 (de)
ZA (1) ZA9410091B (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6197789B1 (en) 1995-06-07 2001-03-06 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
US5622975A (en) * 1995-06-01 1997-04-22 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell migration
US6545027B1 (en) * 1995-06-07 2003-04-08 Eli Lilly And Company Methods of modulating NF-kB transcription factor
ES2180702T3 (es) * 1995-06-07 2003-02-16 Lilly Co Eli Tratamiento de patologias por la induccion del factor de transcripcion bef-1.
US5731328A (en) * 1995-10-10 1998-03-24 Eli Lilly And Company Methods of inhibiting plasminogen activator inhibitor 1
IL120266A (en) 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) * 1996-02-28 2001-06-23 Pfizer New therapeutic uses of estrogen agonists
EP0801066A1 (de) * 1996-03-12 1997-10-15 Eli Lilly And Company Heterozyklisch substituierte Benzothiophene und pharmazeutische Zusammensetzungen
US5811437A (en) * 1996-05-21 1998-09-22 Eli Lilly And Company Methods of increasing nitric oxide synthesis
US5747509A (en) * 1996-06-03 1998-05-05 Schering Aktiengesellschaft Method for lowering plasma levels of lipoprotein(a)
US5980938A (en) * 1996-07-15 1999-11-09 Eli Lilly And Company Effect of compounds that suppress induction of plasminogen activator inhibitor 1 (PAI-1)
US6069175A (en) * 1996-11-15 2000-05-30 Pfizer Inc. Estrogen agonist/antagonists treatment of atherosclerosis
US6353003B1 (en) 1998-06-17 2002-03-05 Eli Lilly And Company Method for reducing levels of homocysteine and C-reactive protein
EP1108434B1 (de) 1998-08-24 2014-05-14 Kurokawa, Kiyoshi Medikamente zur verringerung der carbonylbelastung und peritonealdialysate
RU2464794C1 (ru) * 2011-10-25 2012-10-27 Канапья Табылдыевич Шагиев Состав для производства кисломолочного продукта "курт"
CN103768601A (zh) * 2012-10-22 2014-05-07 中国科学院上海生命科学研究院 抑制micro-RNA155用于预防和治疗动脉粥样硬化的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3983245A (en) * 1975-02-06 1976-09-28 Smithkline Corporation Certain 4-(3-azacycloalkoxy or azacycloalkylmethoxy)benzoylbenzofurans or benzothiophenes
US4418068A (en) * 1981-04-03 1983-11-29 Eli Lilly And Company Antiestrogenic and antiandrugenic benzothiophenes
TW383306B (en) * 1992-12-22 2000-03-01 Lilly Co Eli New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol

Also Published As

Publication number Publication date
EP1095654A3 (de) 2001-06-13
DK0664121T3 (da) 2001-12-03
ZA9410091B (en) 1996-06-19
NO313083B1 (no) 2002-08-12
UA39941C2 (uk) 2001-07-16
PT963756E (pt) 2004-06-30
EP1095654B1 (de) 2003-11-19
CA2138508A1 (en) 1995-06-22
JPH07196498A (ja) 1995-08-01
HUT71476A (en) 1995-11-28
HU9403660D0 (en) 1995-02-28
IL112034A (en) 1999-03-12
TW427902B (en) 2001-04-01
DE69433348T2 (de) 2004-08-26
RU2127592C1 (ru) 1999-03-20
CZ320494A3 (en) 1995-09-13
ES2210089T3 (es) 2004-07-01
KR950016722A (ko) 1995-07-20
EP0963756B1 (de) 2004-02-25
DE69433578T2 (de) 2004-12-16
CZ286365B6 (cs) 2000-03-15
NO944913D0 (no) 1994-12-19
EP0963756A3 (de) 1999-12-22
EP0664121B1 (de) 2001-10-31
PT664121E (pt) 2002-03-28
AU8156394A (en) 1995-06-29
ATE260104T1 (de) 2004-03-15
DK1095654T3 (da) 2004-03-15
RU94045270A (ru) 1996-10-20
DE69428882T2 (de) 2002-04-25
NZ270162A (en) 1997-06-24
PT1095654E (pt) 2004-04-30
CN1108090A (zh) 1995-09-13
EP0963756A2 (de) 1999-12-15
ATE207749T1 (de) 2001-11-15
EP1095654A2 (de) 2001-05-02
ATE254459T1 (de) 2003-12-15
ES2215270T3 (es) 2004-10-01
NO944913L (no) 1995-06-22
AU698389B2 (en) 1998-10-29
DE69428882D1 (de) 2001-12-06
IL112034A0 (en) 1995-03-15
CN1095663C (zh) 2002-12-11
ES2163425T3 (es) 2002-02-01
EP0664121A1 (de) 1995-07-26
DE69433578D1 (de) 2004-04-01

Similar Documents

Publication Publication Date Title
DE69433348D1 (de) Verwendung von Raloxifen und dessen Analogen zur Herstellung eines Medikaments zur Hemmung der LDL Oxidation und der Atherosclerose
ATE199642T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung des knorpelabbaus
AU7578694A (en) Methods for treating resistant neoplasms
DE69428325T2 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen Derivaten zur Herstellung eines Medikaments zur Hemmung der Angiogenese und angiogene Krankheiten
NZ296285A (en) Inhibiting physiological conditions associated with bradykinin using a benzothiophene such as raloxifene
NO20000750D0 (no) Fremgangsmåte for å redusere blodplatetall
ATE200623T1 (de) Verwendung von 2-phenyl-3-aroylbenzothiophen derivaten zur herstellung eines medikaments zur hemmung der primären endometriumhyperplasie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee